LP
MRNA icon

LMR Partners’s Moderna MRNA Stock Holding History

LMR Partners’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.42M Buy
63,055
+62,356
+8,921% +$3.23M 0.02% 695
2026
Q1 		$35.5K Sell
699
-103,068
-99% -$4.81M ﹤0.01% 1327
2025
Q4 		$3.06M Buy
103,767
+70,958
+216% +$1.93M 0.01% 710
2025
Q3 		$847K Sell
32,809
-19,944
-38% -$556K ﹤0.01% 989
2025
Q2 		$1.46M Buy
52,753
+41,353
+363% +$1.09M 0.01% 711
2025
Q1 		$323K Buy
+11,400
New +$405K ﹤0.01% 994
2024
Q4 		– Sell
-350,133
Closed -$16.7M – 1463
2024
Q3 		$23.4M Buy
350,133
+296,232
+550% +$27.2M 0.19% 97
2024
Q2 		$6.4M Buy
+53,901
New +$6.82M 0.05% 276
2022
Q3 		– Sell
-45,844
Closed -$6.55M – 1277
2022
Q2 		$6.55M Sell
45,844
-31,459
-41% -$4.5M 0.11% 229
2022
Q1 		$13.3M Buy
+77,303
New +$13M 0.15% 142
2021
Q2 		– Sell
-35,100
Closed -$4.6M – 1253
2021
Q1 		$4.6M Sell
35,100
-75,996
-68% -$11M 0.11% 169
2020
Q4 		$11.6M Sell
111,096
-188,163
-63% -$19M 0.18% 61
2020
Q3 		$21.2M Buy
+299,259
New +$20.9M 0.44% 31

Other funds holding MRNA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.68B AUM 19.9% 1-Year Est. Return

LMR Partners's MRNA Position: Q2 2026 in Review

LMR Partners increased its Moderna (MRNA) stake by 8,921% in Q2 2026, buying an estimated $3.23M and bringing the position to 63,055 shares worth $4.42M. The position accounts for 0.02% of the portfolio, ranked #695.

LMR Partners first reported a position in MRNA in Q3 2020 and has held it in 13 quarters since. The position peaked at $23.4M in Q3 2024. 782 funds tracked by Wall St. Rank hold MRNA as of Q2 2026.

  • LMR Partners held 63,055 shares of Moderna worth $4.42M as of Q2 2026.
  • LMR Partners bought 62,356 Moderna shares in Q2 2026, an estimated $3.23M.
  • Moderna made up 0.02% of LMR Partners's portfolio in Q2 2026, its #695 holding.
  • LMR Partners first reported a position in Moderna in Q3 2020 and has held it in 13 quarters since.
  • LMR Partners's Moderna position peaked at $23.4M in Q3 2024.
  • 782 funds tracked by Wall St. Rank held Moderna as of Q2 2026.

Based on LMR Partners's 13F filing for Q2 2026, filed 14 Aug 2026.